# US 2025/0367298 A1 · Tamper Resistant Pharmaceutical Formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367298 A1
- Document ID: US20250367298A1
- Status: Published application
- Kind: A1
- Application number: 19/188,674
- Filed: 2025-04-24
- Published: 2025-12-04
- Earliest claimed: 2013-02-05
- Assignees: Purdue Pharma L.P.
- Applicants: Purdue Pharma L.P.
- Inventors: Debora Guido; Haiyong Hugh Huang
- Web page: https://patentgrep.com/patent/US20250367298A1

## CPC

- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 47/02: Inorganic compounds
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/36: Opioid-abuse
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 31/717: Celluloses
- A61K 31/74: Synthetic polymeric materials
- A61K 31/78: of acrylic acid or derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.

## Claims

### Claim 1

A solid oral dosage form comprising a
a heat-labile gelling agent;
a thermal stabilizer; and
a drug susceptible to abuse.

### Claim 2 (depends on 1)

The solid oral dosage form of claim 1, wherein the heat-labile gelling agent is a polymer.

### Claim 3 (depends on 2)

The solid oral dosage form of claim 2, wherein the polymer is a polysaccharide.

### Claim 4 (depends on 3)

The solid oral dosage form of claim 3, wherein the polysaccharide is a microbial polysaccharide.

### Claim 5 (depends on 4)

The solid oral dosage form of claim 4, wherein the microbial polysaccharide is xanthan gum.

### Claim 6 (depends on 1)

The solid oral dosage form of claim 1, wherein the thermal stabilizer is a gelling agent different than the heat labile gelling agent.

### Claim 7 (depends on 6)

The solid oral dosage form of claim 6, wherein the thermal stabilizer gelling agent is a polymer

### Claim 8 (depends on 7)

The solid oral dosage form of claim 7, wherein the thermal stabilizer gelling agent polymer is an anionic polymer in a neutral pH aqueous solution.

### Claim 9 (depends on 8)

The solid oral dosage form of claim 8, wherein the anionic polymer is a polyacrylic acid.

### Claim 10 (depends on 9)

The solid oral dosage form of claim 9, wherein the polymer is carbomer homopolymer.

### Claim 11 (depends on 10)

The solid oral dosage form of claim 10, wherein the heat-labile gelling agent is a polysaccharide.

### Claim 12 (depends on 11)

The solid oral dosage form of claim 11, wherein the polysaccharide is a microbial polysaccharide.

### Claim 13 (depends on 1)

The solid oral dosage form of claim 1, wherein the heat-labile gelling agent is xanthan gum and the thermal stabilizer is carbomer homopolymer.

### Claim 14 (depends on 1)

The solid oral dosage form of claim 1, further comprising a pH-modifying agent.

### Claim 15 (depends on 14)

The solid oral dosage form of claim 14, wherein the pH-modifying agent provides a pH of between about 5.5 and 8.5 to a viscous solution obtained when the dosage form is crushed and mixed with 5 mL of distilled water.

### Claim 16 (depends on 15)

The solid oral dosage form of claim 15, wherein the pH-modifying agent provides a pH of between about 6 and 8.

### Claim 17 (depends on 16)

The solid oral dosage form of claim 16, wherein the pH-modifying agent provides a pH of between about 6.5 and 7.5.

### Claim 18 (depends on 14)

The solid oral dosage form of claim 14, wherein the pH-modifying agent is sodium bicarbonate.

### Claim at position 19

19-146. (canceled)

### Claim 147 (depends on 1)

A method of treating a disease or condition comprising administering to a patient in need thereof, a solid oral dosage form according to claim 1.

### Claim 148

(canceled)

### Claim 149

A method of preparing a solid oral dosage form comprising combining a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse to form a unitary or multiparticulate dosage form.

### Claim 150

(canceled)
